Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Study clarity
Things to check before joining
Study start dateStarted: March 15, 2024
Recruitment status
Active Not Recruiting
Enrollment listed in the registry
71
Sponsor
Anavex Life Sciences Corp.
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT06245213
Official title
Show the full official title
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Electrophysiology of ANAVEX3-71 in Adult Patients With Schizophrenia in a Multiple Ascending Dose Study (Part A), Followed by a Double-Blind, Randomized, Placebo-Controlled Study (Part B)
Questions about this study?
The HopeStage team will email you.
Recruitment & locations
Not recruiting
Marlton
A listed location does not confirm current availability.
FAQ
Questions about this study
Who is behind this study?
The study sponsor is Anavex Life Sciences Corp.
Does this study involve medication?
Yes. The study involves medication, including ANAVEX3-71 oral capsules and Placebo oral capsules.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.